Literature DB >> 937360

Mitral valve prolapse. Recent concepts and observations.

J M Aranda, B Befeler, N El-Sherif, A Castellanos, R Lazzara.   

Abstract

The conditions associated with prolapse of the posterior leaflet of the mitral valve are multiple. The mechanisms of mitral valve prolapse as well as the pathogenesis of pain and ectopic impulse formation are reviewed. Propranolol appears to be the drug of choice for the symptomatic treatment of patients with this syndrome since it decreases myocardial oxygen demand and wall tension thus reducing or abolishing the discrepancy between myocardial oxygen demand and supply within the mitral apparatus. It has also been reported to modify the auscultatory findings associated with this condition. The frequency of this mitral valve abnormality in patients with obstructive coronary artery disease is reviewed. It appears that prolapse of the posterior leaflet scallops in patients with significant obstructive coronary artery disease represents an intermediate stage before mitral insufficiency occurs. This group of patients with papillary muscle dysfunction includes those with prolapsed leaflets without mitral insufficiency, those with systolic murmurs and compensated heart failure and others with progressive cardiac decompensation and severe mitral regurgitation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 937360     DOI: 10.1016/0002-9343(76)90571-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  Mitral valve apparatus. A spectrum of normality relevant to mitral valve prolapse.

Authors:  A E Becker; A P De Wit
Journal:  Br Heart J       Date:  1979-12

2.  Prevalence of mitral valve prolapse in hypertension.

Authors:  G M Holgado; R Prakash
Journal:  J Natl Med Assoc       Date:  1987-09       Impact factor: 1.798

3.  MITRAL VALVE PROLAPSE AND CONGENITAL PYLORIC STENOSIS IN IDENTICAL TWINS.

Authors:  Surender Vuthoori; Earl F. Beard
Journal:  Cardiovasc Dis       Date:  1979-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.